CGT Talk Series 2025: PoC manufacturing potential

If you cannot read this email, please click here.

Miltenyi Biotec



CGT Talk Series 2025

Dear Dr. Macs Mustermann,

Our third topic of the year brings the point-of-care (PoC) cell manufacturing model to center stage. As a decentralized approach, where cell therapies are produced locally at or near hospitals, it presents a transformative opportunity to expand access to life-saving treatments.[1]

Take a look at varying approaches from around the world and continue to share the knowledge.

Kind regards,
Georgia Fodelianaki
Product Manager, Miltenyi Biotec



Academic model for CAR T development in multiple myeloma: clinical results with ARI0002h and future plans

Prof. Carlos Fernández De Larrea, Hospital Clinic, Barcelona, will share insights on an academic CAR T model for multiple myeloma, ARI0002h trial results, and in-hospital therapy as a point-of-care option for relapsed/refractory patients.


Watch now



Enabling effective simultaneous immunosuppression and support of immune regulation by CRISPR/Cas9 edited tacrolimus-resistant Tregs

Leila Amini, PhD, Head of Regulatory Affairs at BeCAT, Charité, will discuss CRISPR-edited, tacrolimus-resistant Tregs for immune regulation during immunosuppression, covering GMP-manufacturing, regulatory progress, and solid organ transplant trials.

Watch now



Development of CD19 CAR T IIT in Korea

Hear from **Prof. Hyoung Jin Kang**, MD, PhD, Pediatric hematology/oncology at Seoul National University Hospital, South Korea. This presentation will detail the development of Korea's first investigator-initiated CAR T cell trial for pediatric and adolescent ALL at Seoul National University.

Watch now

---

1. CDER, U.S. FDA. (2022) Distributed Manufacturing and Point-of-Care Manufacturing of Drugs.

Follow us:

If you wish to update your profile please click here.

Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use. For further regulatory notes, refer to https://www.miltenyibiotec.com/regulatory-notes.html.

Copyright © 2025 Miltenyi Biotec B.V. & Co. KG and/or its affiliates. All rights reserved. Miltenyi Biotec B.V. & Co. KG, Friedrich-Ebert-Straße 68, 51429 Bergisch Gladbach, Germany, Registered Office: Bergisch Gladbach - Germany, Commercial Register: AG Köln HRA 34194, Managing Directors: Dipl.-Phys. Stefan Miltenyi, Dr. Boris Stoffel, Dipl.-Vw. Norbert Hentschel, Dr. Jürgen Schmitz, Dr. Antoon Overstijns, VAT-ID: DE 815 828 586

Home | Legal notes | Privacy statement | Contact us | Unsubscribe